HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.00950208v1 3/5/1526    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kato, S. Articles by Lindholm, B. Search for Related Content PubMed PubMed Citation Articles by Kato, S. Articles by Lindholm, B.

Aspects of Immune Dysfunction in End-stage Renal Disease

Sawako Kato^*,, Michal Chmielewski^*,, Hirokazu Honda, Roberto Pecoits-Filho^||, Seiichi Matsuo, Yukio Yuzawa, Anders Tranaeus^*, Peter Stenvinkel^*, and Bengt Lindholm^*

^* Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Division of Clinical Immunology, Department of Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland; Department of Nephrology, Showa University School of Medicine, Tokyo, Japan; ^|| Centro de Ciencias Biologicas e da Saude, Pontificia Universidade Catolica do Parana, Curitiba, Brazil

Correspondence: Dr. Bengt Lindholm, Divisions of Renal Medicine and Baxter Novum, K-56 Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden. Phone: +46858582601; Fax: +46858583925; E-mail: bengt.lindholm{at}ki.se

End-stage renal disease (ESRD) is associated with significantly increased morbidity and mortality resulting from cardiovascular disease (CVD) and infections, accounting for 50% and 20%, respectively, of the total mortality in ESRD patients. It is possible that these two complications are linked to alterations in the immune system in ESRD, as uremia is associated with a state of immune dysfunction characterized by immunodepression that contributes to the high prevalence of infections among these patients, as well as by immunoactivation resulting in inflammation that may contribute to CVD. This review describes disorders of the innate and adaptive immune systems in ESRD, underlining the specific role of ESRD-associated disturbances of Toll-like receptors. Finally, based on the emerging links between the alterations of immune system, CVD, and infections in ESRD patients, it emphasizes the potential role of the immune dysfunction in ESRD as an underlying cause for the high mortality in this patient population and the need for more studies in this area.

This article has been cited by other articles:

				K. S. Rogacev, M. Ziegelin, C. Ulrich, S. Seiler, M. Girndt, D. Fliser, and G. H. Heine Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3480 - 3486. [Abstract] [Full Text] [PDF]

				D. J. de Jager, D. C. Grootendorst, K. J. Jager, P. C. van Dijk, L. M. J. Tomas, D. Ansell, F. Collart, P. Finne, J. G. Heaf, J. De Meester, et al. Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis JAMA, October 28, 2009; 302(16): 1782 - 1789. [Abstract] [Full Text] [PDF]

				H. K. Smerud, B. Fellstrom, R. Hallgren, S. Osagie, P. Venge, and G. Kristjansson Gluten sensitivity in patients with IgA nephropathy Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2476 - 2481. [Abstract] [Full Text] [PDF]

				R. Pecoits-Filho APPLYING TRANSLATIONAL RESEARCH IN UNDERSTANDING COMPLICATIONS AND DEFINING TARGETS FOR INTERVENTION: INFLAMMATION IN PD AS A MODEL Perit. Dial. Int., March 1, 2009; 29(2): 135 - 141. [Abstract] [Full Text] [PDF]